INTRODUCTION AND OBJECTIVES: Multi-parametric MRI (mpMRI) has revolutionized prostate diagnostics in improving the detection and accuracy of biopsies. mpMRI however remains a resource intensive tool and has operator dependent variability in its performance. Here we tested the value of PHI test in reducing and refining the use of mpMRI in prostate diagnostics.
INTRODUCTION AND OBJECTIVES: Multi-parametric MRI (mpMRI) has revolutionized prostate diagnostics in improving the detection and accuracy of biopsies. mpMRI however remains a resource intensive tool and has operator dependent variability in its performance. Here we tested the value of PHI test in reducing and refining the use of mpMRI in prostate diagnostics.
METHODS: This study represents the initial findings of the ongoing prospective UK PRIM study. 289 men referred for the first time to a prostate diagnostic clinic in our centre had a PHI assay done prior to image-targeted fusion biopsy þ systematic biopsies. mpMRI were scored using the Likert scale. Men with no mpMRI lesion had systematic biopsies. Measured parameters included PSA, PSA density (PSAd), PHI, PHI density and outcomes of interest were mpMRI positivity, and any and significant cancer detection (Grade Group 2 or more). Prostate volume was derived from the mpMRI measurements.
RESULTS: The median age was 65y (IQR 59-69), PSA 8.5ng/ ml (IQR5.6-12.4) and PHI 42 . 212/289 men (73%) were mpMRI positive. 183/289 (63%) and 126/289 (44%) had any and significant cancers detected respectively. The median PHI was 47 (IQR 34-72) and 33 (IQR 24-43) in mpMRI positive and negative men respectively and 61 ( IQR 44-81) and 34 (IQR 26-44) for significant cancers and non-significant cancers/benign lesions.
In multivariate logistic regression, PHI was an independent predictor of a positive mpMRI (OR 1.7, 1.4-2.0) after adjustment for PSA, with an AUC of 0.72 (0.68-0.72) compared to 0.51 (0.44-0.58) for PSA (p<0.0005).
PHI outperformed both mpMRI and PSAd in predicting significant cancer detection; AUC 0.81 (0.76-0.86) versus 0.68 (0.64-0.73) and 0.76 (0.71-0.82). It also outperformed mpMRI and PSAd in detection of any cancer though differences here were much smaller: AUC 0.77 (0.72-0.83) versus 0.71 (0.66-0.76) and 0.74 (0.68-0.80) respectively.
The combination of mpMRI and PHI had the highest predictive value for a significant cancer or any cancer ). Additional derivation of the PHI density did not add the performance characteristics in this study.
Amongst mpMRI negative men, the AUC for predicting a significant cancer was 0.79 (0.63-0.95) and 0.68 (0.48-0.89) for PHI and PSAd respectively. For any cancer detection these values were 0.68 (0.54-0.81) and 0.62 (0.47-0.76) respectively.
Using an initial threshold PHI of !30 as a cut-point for referrals and biopsying only men with a positive mpMRI would have saved 23% mpMRI and biopsies and missed only 7/126 significant cancers (6%).
CONCLUSIONS: Use of the PHI as an initial triage test can reduce the need for men to enter the diagnostic pathway, offering savings on imaging and biopsies yet still retaining a high level of significant cancer detection. Ongoing work will continue to evaluate its use in a larger multi-center cohort along with health economic modelling. Prostate health index (PHI) was found to have higher accuracy rate to distinguish malignancy from benign disease compared with prostate specific antigen (PSA). MRI-transrectal ultrasound (TRUS) fusion prostate biopsy also gave a better result for prostate cancer diagnosis, but the correlation is not thoroughly elucidated. We aimed to study the predictive power of PHI on the result of MRI-TRUS fusion prostate biopsy.
METHODS: We initiated this prospective study from March 2017 to August 2018. Patients with PSA > 4.0 ng/ml or abnormal finding in digital rectal examination were enrolled. Those patients underwent MRI-TRUS fusion biopsy after blood samples for serum total PSA (tPSA), free PSA (fPSA) and p2PSA. Prostate health index (PHI) was calculated. Receiver operating characteristic (ROC) curve and multivariate analysis were done for all markers between cancer and non-cancer patients.
RESULTS: Total 124 patients were enrolled in this study. ROC curve revealed the area under curve of prostate volume, PSA density, tPSA, fPSA%, p2PSA% and PHI are 0.648, 0.715, 0.564, 0.653, 0.739 and 0.838. PHI gave a best result in distinguishing cancer from non-cancer patients compared with others ( Figure 1) . Besides, PHI has the highest odds ratio (Table 1) .
CONCLUSIONS: PHI not only has the best accuracy for prostate cancer detection in patient underwent systemic prostate biopsy, but also has better predictive power in MRI-TRUS fusion prostate biopsy patients.
INTRODUCTION AND OBJECTIVES: PSA density (PSAD) is a PSA derivative that has been used to help predict for prostate cancer on biopsy. PSAD cut offs were formulated from cohorts consisting of mostly Caucasian (CA) men who underwent a sextant biopsy. We sought to evaluate PSAD in a more modern cohort of men to predict prostate cancer, to predict significant cancer, and to compare the performance of PSAD in African Americans (AA) and CA.
METHODS: After IRB approval, we performed a retrospective chart review of all men who underwent a 12 core prostate biopsy between 2015 and 2017 at LSU Shreveport. Data collected included age, race, BMI, finasteride use, PSA, prostate volume (PV), biopsy pathology, T stage and Gleason score. PSA was corrected for finasteride use. PSA density was calculated by PSA divided by PV. Receiver operator characteristic (ROC) curve analysis was performed using the entire cohort, the AA cohort, and the CA cohort to predict for prostate cancer and significant cancer. Significant cancer was defined two ways using the AUA risk groups: 1. Intermediate (favorable and unfavorable) and high risk groups 2. Unfavorable intermediate and high risk groups.
RESULTS: Of the entire cohort (n[239), 68.2% (n[163), 28.8% (n[69), and 2.9% were AA, CA, and other, respectively. Including 91 AA and 27 CA, 49.3% had a positive biopsy.
The area under the curve (AUC) to predict prostate cancer was 0.784 (95% CI 0.726-0.841), 0.761 (95% CI 0.688-0.834), and 0.814 (95% CI 0.711-0.916) using the entire, AA, and CA cohorts, respectively.
Using definition 1 for significant cancer, the AUC for the entire, AA, and CA cohorts was 0.796 (95% CI 0.738-0.854), 0.777 (95% CI 0.705-0.85), and 0.824 (95% CI 0.714-0.935), respectively.
Using definition 2 for significant cancer, the AUC for the entire, AA, and CA cohorts was 0.841 (95% CI 0.786-0.895), 0.814 (95% CI 0.745-0.883), and 0.905 (95% CI 0.83-0.98), respectively. Table 1 lists the sensitivity (Se) and specificity (Sp) for selected PSAD cut off scores to predict a positive biopsy for the entire, AA, and CA cohorts.
CONCLUSIONS: PSAD is still a useful tool and can be used to help counsel patients about undergoing a prostate biopsy. PSAD performed better in Caucasian men than African American men in predicting prostate cancer and significant cancer. Prostate specific antigen (PSA) has been a useful screening tool in identifying prostate cancer since its discovery. However relying on PSA alone has shown poor performance in prostate cancer detection. It is envisaged that measuring PSA density can possibly enhance its predictive value in detecting cancers, however it is not standard practice or recommended in national guidelines. Previous studies have shown that PSA density is most useful when the PSA is in the range of 4-10ng/ml due to diagnostic uncertainty within that range.
We aim to study the effectiveness of PSA density at detecting prostate cancer within that range as well as outside that range.
METHODS: Retrospective single centre study at North West Anglia NHS Trust including 500 patients who had a mp-MRI prior to prostate biopsy between July 2017 to July 2018. Patients undergoing repeat biopsy already on a cancer pathway were excluded. PSA density was calculated by dividing PSA over the prostate volume as recorded on the mp-MRI.
RESULTS: Data was collected from 500 patients with a mean age of 65 and mean PSA of 10.7ng/ml. A total of 321 (64.2%) patients had a PSA between 4-10 ng/ml. The mean PSA density within that range was calculated for each Gleason score and found to be 0.11 ng/ml/cm3 for benign, 0.13 for Gleason 6, 0.16 for Gleason 7, 0.18 for Gleason 8 and 0.21 for Gleason 9. Overall the mean PSA density in prostate cancer was found to be 0.15 and 0.17 in clinically significant prostate cancer defined as Gleason score ! 7.
There is a statistically significant difference between the mean PSA density values of cancer positive biopsies vs benign (T test p<0.001). A cut off value of PSA density was chosen at 0.15 and 0.10. Sensitivity of 0.10 at detecting all prostate cancer with PSA 4-10 was 76% and 88% for clinically significant prostate cancer. The negative predictive value was 94% for clinically significant prostate cancer.
With PSA of <4 or >10 and PSA density of 0.10 the sensitivity was 93% (all cancer) and 96.6% (Gleason ! 7) with a negative predictive value of 93.7% for clinically significant prostate cancer.
At a cut off PSA density of 0.15 sensitivity and negative predictive value was 39% and 65% (all prostate cancer) and 50% and 87% (Gleason 7 and above) respectively with PSA of 4-10.
CONCLUSIONS: PSA density usage can help improve the accuracy of detecting prostate cancer and thus reduce the number of unnecessary prostate biopsies. A cut off value of 0.10 ng/ml/cm3 has a higher sensitivity and negative predictive value, especially when compared against clinically significant cancer.
